Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francisco Aya

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cell Genomics|June 13, 2024
Shaping human brain development and vulnerability through alternative splicingFrancisco Aya, Juan Valcárcel
Immunotherapy|April 28, 2021
Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communicationFrancisco Aya, E Azucena González-Navarro, Clara Martínez, et al.
Future Oncology (London, England)|September 2, 2016
Ipilimumab after progression on anti-PD-1 treatment in advanced melanomaFrancisco Aya, Lydia Gaba, Iván Victoria, et al.
Cancers|November 13, 2021
A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLCFrancisco Aya, Mariana Benegas, Nuria Viñolas, et al.
Immunotherapy|April 27, 2016
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumabFrancisco Aya, Aranzazu Fernández-Martínez, Lydia Gaba, et al.
Clinical and Experimental Dermatology|January 23, 2026
Pembrolizumab Therapy Leads to Lentigines Resolution and Tumour Control in a Xeroderma Pigmentosum patient with Advanced Cutaneous Squamous Cell CarcinomaMagí Brufau-Cochs, Sofia Gómez-Martínez, Francisco Aya, et al.
International Journal of Molecular Sciences|September 14, 2024
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current KnowledgeClara Martínez-Vila, Europa Azucena González-Navarro, Cristina Teixido, et al.
Cell Reports|April 13, 2024
Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaFrancisco Aya, Pablo Lanuza-Gracia, Abel González-Pérez, et al.
International Journal of Molecular Sciences|January 25, 2025
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in MelanomaClara Martínez-Vila, Cristina Teixido, Francisco Aya, et al.
Journal of Diabetes Investigation|May 28, 2021
Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case reportLaura Boswell, Gregori Casals, Jesús Blanco, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cell Genomics|June 13, 2024
Shaping human brain development and vulnerability through alternative splicingFrancisco Aya, Juan Valcárcel
Immunotherapy|April 28, 2021
Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communicationFrancisco Aya, E Azucena González-Navarro, Clara Martínez, et al.
Future Oncology (London, England)|September 2, 2016
Ipilimumab after progression on anti-PD-1 treatment in advanced melanomaFrancisco Aya, Lydia Gaba, Iván Victoria, et al.
Cancers|November 13, 2021
A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLCFrancisco Aya, Mariana Benegas, Nuria Viñolas, et al.
Immunotherapy|April 27, 2016
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumabFrancisco Aya, Aranzazu Fernández-Martínez, Lydia Gaba, et al.
Clinical and Experimental Dermatology|January 23, 2026
Pembrolizumab Therapy Leads to Lentigines Resolution and Tumour Control in a Xeroderma Pigmentosum patient with Advanced Cutaneous Squamous Cell CarcinomaMagí Brufau-Cochs, Sofia Gómez-Martínez, Francisco Aya, et al.
International Journal of Molecular Sciences|September 14, 2024
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current KnowledgeClara Martínez-Vila, Europa Azucena González-Navarro, Cristina Teixido, et al.
Cell Reports|April 13, 2024
Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaFrancisco Aya, Pablo Lanuza-Gracia, Abel González-Pérez, et al.
International Journal of Molecular Sciences|January 25, 2025
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in MelanomaClara Martínez-Vila, Cristina Teixido, Francisco Aya, et al.
Journal of Diabetes Investigation|May 28, 2021
Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case reportLaura Boswell, Gregori Casals, Jesús Blanco, et al.
Pageof 3